ImmuneWorks is developing novel antigen-specific therapies and complimentary diagnostic tests for serious lung diseases including lung transplant rejection and idiopathic pulmonary fibrosis. A common disease pathway that was discovered by ImmuneWorks founder and Chief Science Officer David Wilkes, MD of the Indiana University School of Medicine links these diseases. Dr. Wilkes' discovery of autoimmunity to type V collagen in these diseases characterized by extensive interstitial remodeling and exposure or overexpression of type V collagen has led to the development of antigen-specific therapies and diagnostic tests by ImmuneWorks.

To learn more about ImmuneWorks Science please click on the following link: IW Science Background

Key Journal Articles:

	TH-17, Monokines, Collagen Type V, and Primary Graft Dysfunction in Lung Transplantation		Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis
	IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants		Global Impairment of CD4+CD25+FOXP3+ Regulatory T Cells in Idiopathic Pulmonary Fibrosis
	Anti-Type V Collagen Humoral Immunity in Lung Transplant Primary Graft Dysfunction

Videos:

For more information, please contact ImmuneWorks co-founder and Chief Science Officer David Wilkes, MD at david.wilkes@immuneworks.com.